10.6084/m9.figshare.1569651.v4
Nishi Kothari
Nishi
Kothari
Richard Kim
Richard
Kim
Robert N. Jorissen
Robert
N. Jorissen
Jayesh Desai
Jayesh
Desai
Jeanne Tie
Jeanne
Tie
Hui-Li Wong
Hui-Li
Wong
Ian Farragher
Ian
Farragher
Ian Jones
Ian
Jones
Fiona L. Day
Fiona
L. Day
Shan Li
Shan
Li
Anuratha Sakthinandeswaren
Anuratha
Sakthinandeswaren
Michelle Palmieri
Michelle
Palmieri
Lara Lipton
Lara
Lipton
Michael Schell
Michael
Schell
Jamie K. Teer
Jamie
K. Teer
David Shibata
David
Shibata
Timothy Yeatman
Timothy
Yeatman
Oliver M. Sieber
Oliver
M. Sieber
Peter Gibbs
Peter
Gibbs
Ben Tran
Ben
Tran
Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation
Taylor & Francis Group
2015
Multivariate survival analyses
Royal Melbourne Hospital
Regular aspirin use
PIK 3CA tumors
hr
colorectal cancer
Prospective clinicopathological data
Moffitt Cancer Center
PIK 3CA CRC patients
PIK 3CA mutation
PIK 3CA mutation Background
aspirin use
rmh
PIK 3CA CRC.Patients
1487 CRC patients
mcc
PIK 3CA CRC
Generation Sequencing platform
PIK 3CA mutations
2015-10-08 17:11:55
Journal contribution
https://tandf.figshare.com/articles/journal_contribution/Impact_of_regular_aspirin_use_on_overall_and_cancer_specific_survival_in_patients_with_colorectal_cancer_harboring_a_PIK3CA_mutation/1569651
<div><p></p><p><b>Background.</b> Recent data have suggested that regular aspirin use improves overall and cancer-specific survival in the subset of colorectal cancer (CRC) patients harboring <i>PIK3CA</i> mutations. However, the number of <i>PIK3CA</i>-mutated CRC patients examined in these studies was modest. Our collaborative study aims to validate the association between regular aspirin use and survival in patients with <i>PIK3CA</i>-mutated CRC.</p><p><b>Patients and methods.</b> Patients with <i>PIK3CA</i>-mutated CRC were identified at Moffitt Cancer Center (MCC) in the United States and Royal Melbourne Hospital (RMH) in Australia. Prospective clinicopathological data and survival data were available. At MCC, <i>PIK3CA</i> mutations were identified by targeted exome sequencing using the Illumina GAIIx Next Generation Sequencing platform. At RMH, Sanger sequencing was utilized. Multivariate survival analyses were conducted using Cox logistic regression.</p><p><b>Results.</b> From a cohort of 1487 CRC patients, 185 patients harbored a <i>PIK3CA</i> mutation. Median age of patients with PIK3CA-mutated tumors was 72 years (range: 34–92) and median follow up was 54 months. Forty-nine (26%) patients used aspirin regularly. Regular aspirin use was not associated with improved overall survival (multivariate HR 0.96, p = 0.86). There was a trend towards improved cancer-specific survival (multivariate HR 0.60, p = 0.14), but this was not significant.</p><p><b>Conclusions.</b> Despite examining a large number of patients, we did not confirm that regular aspirin use was associated with statistically significant improvements in survival in PIK3CA-mutated CRC patients. Prospective evaluation of this relationship is warranted.</p></div>